Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium chloride - cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, eg radiotherapy or surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; mannitol; water for injections - cisplatin injection is indicated for the palliative treatment of metastatic non-seminomatous germ cell carcinoma, advanced-stage refractory ovarian carcinoma, advanced-stage refractory bladder carcinoma and refractory squamous cell carcinoma of the head and neck. it may be used as a single agent or in combination with other chemotherapeutic agents. it may be employed, in appropriate circumstances, in addition to other modalities, eg radiotherapy or surgery.

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - cisplatin - concentrate for solution for infusion - cisplatin 1 mg/ml - antineoplastic agents

Namibia - English - Namibia Medicines Regulatory Council

pharmaplan (pty) ltd - cisplatin - injection - cisplatin injection, 1mg/ml

United States - English - NLM (National Library of Medicine)

fosun pharma usa inc - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, s

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: metastatic testicular tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. metastatic ovarian tumors in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. advanced bladder cancer cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal impairment. cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum-containing compounds.

Australia - English - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited t/a radpharm scientific - bicisate dihydrochloride, quantity: 0.9 mg - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate; water for injections - [99mtc]-bicisate scintigraphy is indicated in the evaluation and localisation of regional perfusion abnormalities in adult patients with the central nervous system disorders of stroke and dementia.

United States - English - NLM (National Library of Medicine)

lantheus medical imaging, inc. - bicisate dihydrochloride (unii: b005p07v07) (bicisate - unii:3jxf0z0xoi) - bicisate dihydrochloride 0.9 mg - neurolite single photon emission computerized tomography (spect) is indicated as an adjunct to conventional ct or mri imaging in the localization of stroke in patients in whom stroke has already been diagnosed. neurolite is not indicated for assessment of functional viability of brain tissue. also, neurolite is not indicated for distinguishing between stroke and other brain lesions. none known.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - cisplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, intravenous infusion - excipient ingredients: mannitol; sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - cisplatin is indicated for the treatment of: metastatic non-seminomatous germ cell carcinoma advanced and refractory carcinoma of the ovary; advanced and refractory carcinoma of the bladder; squamous cell carcinoma of the head and the neck.